Publications by Mélanie Louise Tichet

A new effLuc/Kate dual reporter allele for tumor imaging in mice

Douglas Hanahan, Mélanie Louise Tichet, Elizabeth Anne Allen, Ke Cheng

Genetically engineered mouse models (GEMMs) are instrumental for modelling local and systemic features of complex diseases, such as cancer. Non-invasive, longitudinal cell detection and monitoring in tumors, metastases and/or the micro-environment is param ...

The Company of Biologists2025

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor- reactive CD8+T cells and reprogramming macrophages

Douglas Hanahan, Krisztian Homicsko, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz, Stephan Wullschleger

Immunotherapies have shown remarkable, albeit tumor-selective, therapeutic benefits in the clinic. Most pa-tients respond transiently at best, highlighting the importance of understanding mechanisms underlying resistance. Herein, we evaluated the effects o ...

CELL PRESS2023

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells

Douglas Hanahan, Mélanie Louise Tichet, Stephan Wullschleger, Petra Catalina Schwalie, Maria Karagianni

Expansion and differentiation of antigen-experienced PD-1(+)TCF-1(+) stem-like CD8(+) T cells into effector cells is critical for the success of immunotherapies based on PD-1 blockade(1-4). Hashimoto et al. have shown that, in chronic infections, administr ...

NATURE PORTFOLIO2022

Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion

Douglas Hanahan, Nadine Fournier, Krisztian Homicsko, Mélanie Louise Tichet, Mohammad Sadegh Saghafinia, Agnieszka Alicja Chryplewicz, Dalya Ataca, Qiqun Zeng, Jeremy Gilles Louis Guillot, Simge Yücel

Many human cancers manifest the capability to circumvent attack by the adaptive immune system. In this work, we identified a component of immune evasion that involves frequent up-regulation of fragile X mental retardation protein (FMRP) in solid tumors. FM ...

American Association for the Advancement of Science2022

Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity

Douglas Hanahan, Krisztian Homicsko, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz, Ksenya Shchors, Julie Laetitia Scotton

Glioblastoma (GBM) is poorly responsive to therapy and invariably lethal. One conceivable strategy to circumvent this intractability is to co-target distinctive mechanistic components of the disease, aiming to concomitantly disrupt multiple capabilities re ...

2022

Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma

Douglas Hanahan, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz

AMER ASSOC CANCER RESEARCH2022

Co-targeting autophagy, macrophages and vasculature in glioma tumors triggers tumor immunity

Douglas Hanahan, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz, Julie Laetitia Scotton

AMER ASSOC CANCER RESEARCH2022

The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity

Douglas Hanahan, Mélanie Louise Tichet, Stephan Wullschleger

AMER ASSOC CANCER RESEARCH2021

Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers

Douglas Hanahan, Nadine Fournier, Mélanie Louise Tichet, Melody Swartz, Stephan Wullschleger, Gabriele Galliverti

Cancers induced by human papillomaviruses (HPV) should be responsive to immunotherapy by virtue of expressing the immunogenic oncoproteins E6/E7. However, advanced forms of cervical cancer, driven by HPV, are poorly responsive to immune response-enhancing ...

AMER ASSOC CANCER RESEARCH2020

Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-kappa B signaling pathway

Mélanie Louise Tichet

Cutaneous melanoma is one of the most aggressive cancers characterized by a high plasticity, a propensity for metastasis, and drug resistance. Melanomas are composed of phenotypically diverse subpopulations of tumor cells with heterogeneous molecular profi ...

2019